未知股票 MMAT 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 669.46万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 7.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction
BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction March 11 (Reuters) - VistaGen Therapeutics Inc VTGN.O : VISTAGEN THERAPEUTICS INC - IMPLEMENTS 20% WORKFORCE REDUCTION ON MARCH 5, 2026 - SEC FILING VISTAGEN THERAPEUTICS INC - REDUCTION SUPPORTS CASH MANAGEMENT AND PALISADE PROGRAM CLIN
03-11 19:14
BRIEF-Harrow To Initiate Phase 3 Clinical Trial Seeking To Expand Triesence® Label To Include Ocular Inflammation And Pain Following Cataract Surgery Indication
BRIEF-Harrow To Initiate Phase 3 Clinical Trial Seeking To Expand Triesence® Label To Include Ocular Inflammation And Pain Following Cataract Surgery Indication March 3 (Reuters) - Harrow Inc HROW.O : HARROW TO INITIATE PHASE 3 CLINICAL TRIAL SEEKING TO EXPAND TRIESENCE® LABEL TO INCLUDE OCULAR INFL
03-03 20:29
EXPLAINER-Motor racing-What's changed as Formula One enters a new era
EXPLAINER-Motor racing-What's changed as Formula One enters a new era By Alan Baldwin LONDON, March 2 (Reuters) - The 2026 Formula One season fires up in Melbourne on March 8 with the Australian Grand Prix. The following looks at what has changed in a new era for the sport: NEW CHAMPION McLaren's wo
03-02 20:44
BRIEF-Sanofi And Regeneron’S Dupixent Approved In The U.S. For Allergic Fungal Rhinosinusitis
BRIEF-Sanofi And Regeneron’S Dupixent Approved In The U.S. For Allergic Fungal Rhinosinusitis Feb 24 (Reuters) - Sanofi SA SASY.PA : SANOFI AND REGENERON’S DUPIXENT APPROVED IN THE US AS THE FIRST AND ONLY MEDICINE FOR ALLERGIC FUNGAL RHINOSINUSITIS PHASE 3 STUDY SHOWS DUPIXENT REDUCES NASAL SIGNS A
02-24 22:33
BRIEF-Sigma Defense Secures 7-Year, $102 Mln Contract For Canes Tech And Engineering Services
BRIEF-Sigma Defense Secures 7-Year, $102 Mln Contract For Canes Tech And Engineering Services Feb 23 (Reuters) - Sigma Defense: SIGMA DEFENSE SECURES 7-YEAR, $102M IDIQ CONTRACT FOR CANES TECHNICAL, PROGRAMMATIC AND ENGINEERING SERVICES FOR NETWORKING, COMMUNICATIONS AND COMPUTER SYSTEMS SIGMA DEFEN
02-24 01:26
BRIEF-Evogene, Systasy And Lmu University Hospital Munich Announce A Collaboration To Develop Therapies For Inflammatory Diseases
BRIEF-Evogene, Systasy And Lmu University Hospital Munich Announce A Collaboration To Develop Therapies For Inflammatory Diseases Feb 11 (Reuters) - Evogene Ltd EVGN.TA : EVOGENE, SYSTASY AND LMU UNIVERSITY HOSPITAL MUNICH ANNOUNCE A COLLABORATION TO DEVELOP NOVEL THERAPIES FOR NEUTROPHIL-DERIVED IN
02-11 22:48
BRIEF-Devonian Health Group Inc Reports Positive Results In Pulmonary Fibrosis Study
BRIEF-Devonian Health Group Inc Reports Positive Results In Pulmonary Fibrosis Study Feb 10 (Reuters) - Devonian Health Group Inc GSD.V : DEVONIAN HEALTH GROUP INC: REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY DEVONIAN HEALTH GROUP INC - THYKAMINE™ SHOWS BETTER RESULTS THAN PIRFENIDONE IN ST
02-10 23:44
BRIEF-Medtronic Advances Its Innovation Strategy With Intent To Acquire Cathworks
BRIEF-Medtronic Advances Its Innovation Strategy With Intent To Acquire Cathworks Feb 3 (Reuters) - Medtronic PLC MDT.N : MEDTRONIC ADVANCES ITS INNOVATION STRATEGY WITH INTENT TO ACQUIRE CATHWORKS MEDTRONIC PLC: ACQUISITION IS VALUED AT UP TO $585 MILLION WITH POTENTIAL UNDISCLOSED EARN-OUT PAYMENT
02-03 21:38
BRIEF-Insmed Provides Clinical And Business Update
Dec 17 (Reuters) - Insmed Inc INSM.O: INSMED PROVIDES CLINICAL AND BUSINESS UPDATE INSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS INSME...
2025-12-18 05:03
BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio
Dec 12 (Reuters) - Arcus Biosciences Inc RCUS.N: ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IM...
2025-12-12 21:39
